<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100696">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01736059</url>
  </required_header>
  <id_info>
    <org_study_id>BMSCRetPilot</org_study_id>
    <nct_id>NCT01736059</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy</brief_title>
  <official_title>A Pilot Clinical Trial of the Feasibility and Safety of Intravitreal Autologous Adult Bone Marrow Stem Cells in Treating Eyes With Vision Loss From Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem
      cells from bone marrow into the eye as treatment for patients who are irreversibly blind
      from various retinal conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this pilot clinical trial, eyes with irreversible vision loss from retinal degenerative
      conditions (macular degeneration or retinitis pigmentosa) or retinal vascular disease
      (diabetic retinopathy or retinal vein occlusion) will be treated with intravitreal injection
      of autologous CD34+ stem cells isolated from bone marrow aspirate under Good Manufacturing
      Practice conditions.  This study will determine whether there are any major safety and
      feasibility concerns using this therapy.  Patients will be followed for 6 months after
      treatment by serial comprehensive eye examination supplemented with various retinal imaging
      and diagnostic tests.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence and severity of ocular adverse events</measure>
    <time_frame>1 day to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>As evident on eye examination by severe decrease in vision and/or adverse effect requiring major treatment intervention directly attributable to study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of stem cells isolated and injected into the study eye</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will determine the yield of the bone marrow aspiration and stem cell isolation procedures.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence and severity of systemic adverse events</measure>
    <time_frame>1 day to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any systemic adverse event attributable to the bone marrow aspiration or intravitreal injection of the stem cells.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Dry Age-related Macular Degeneration</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Retina Vein Occlusion</condition>
  <condition>Retinitis Pigmentosa</condition>
  <condition>Hereditary Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Stem cell treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD34+ bone marrow stem cells intravitreal</intervention_name>
    <arm_group_label>Stem cell treated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;18 years of age

          -  visual acuity 20/200 to CF

          -  duration of vision loss &gt; 3 months

          -  vision loss from macular degeneration, retinitis pigmentosa, retinal vein occlusion
             or diabetic retinopathy

          -  the study eye has the worse visual acuity

          -  no active eye or systemic disease

          -  no history of macular edema or retinal/choroidal neovascularization requiring
             treatment within 6 months

          -  no significant media opacity

          -  no coagulopathy or other hematologic abnormality

          -  no concurrent immunosuppressive therapy

          -  able to keep follow-up for 6 months

        Exclusion Criteria:

          -  allergy to fluorescein dye

          -  other concurrent retinal or optic nerve disease affecting vision
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanna s Park, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California Davis Eye Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanna S Park, MD PhD</last_name>
    <phone>916-734-6074</phone>
    <email>susanna.park@ucdmc.ucdavis.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marisa Salvador</last_name>
    <phone>916-734-6302</phone>
    <email>marisa.salvador@ucdmc.ucdavis.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lawrence S Morse, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Nolta, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerhard Bauer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carol Richman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehrdad Abedi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Douglas Taylor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 28, 2014</lastchanged_date>
  <firstreceived_date>July 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem cells</keyword>
  <keyword>intravitreal</keyword>
  <keyword>bone marrow CD34+ cells</keyword>
  <keyword>retinal disease</keyword>
  <keyword>clinical trial</keyword>
  <keyword>autologous</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
